Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain

Status Completed

Clinical Trial Summary

For cancer patients with inadequate pain relief, a switch to an alternative opioid is the preferred option for symptomatic improvement. However, multiple opioids are often simultaneously administered for anecdotal reasons.

The present study isdesigned to assess the analgesic profiles of two different strategies in chronic cancer pain: the opioid rotation from oxycodone to transdermal fentanyl and the combination of oral oxycodone and transdermal fentanyl.

Clinical Trial Description

Patients with uncontrolled cancer pain despite treatment of oral morphine equivalent ≥100 mg/d will be randomly assigned to oral opioids to transdermal fentanyl (rotation group) or oral oxycodone plus fentanyl (combination group). Patients answer a questionnaire that included pain severity (0 to 10) and interference items at baseline and after one week. Primary outcomes are change in pain score and treatment success. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Advanced Solid Cancers

Clinical Trial Details

NCT number	NCT00478101
Study type	Interventional
Source	Gachon University Gil Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	February 2006
Completion date	April 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02792465` - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00886782` - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03956680` - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers	Phase 1
Completed	`NCT03512340` - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers	Phase 1
Terminated	`NCT03254732` - Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers	Phase 1
Terminated	`NCT00337376` - A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers	Phase 1
Completed	`NCT01019941` - Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer	Phase 1
Completed	`NCT02694822` - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy	Phase 1/Phase 2